Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Sees Significant Growth in Short Interest

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 175,300 shares, a growth of 255.6% from the December 31st total of 49,300 shares. Approximately 2.8% of the shares of the company are sold short. Based on an average daily volume of 272,300 shares, the short-interest ratio is presently 0.6 days.

Protagenic Therapeutics Stock Down 7.9 %

Shares of NASDAQ:PTIX opened at $0.47 on Wednesday. Protagenic Therapeutics has a twelve month low of $0.40 and a twelve month high of $1.87. The company has a 50 day moving average of $0.53 and a 200-day moving average of $0.61.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.